Cancer/Testis Antigens as Predictors of Prostate Cancer Recurrence
Author Information
Author(s): Shiraishi Takumi, Terada Naoki, Zeng Yu, Suyama Takahito, Luo Jun, Trock Bruce, Kulkarni Prakash, Getzenberg Robert H
Primary Institution: Johns Hopkins University School of Medicine
Hypothesis
The study aims to identify promising Cancer/Testis Antigens (CTAs) associated with prostate cancer recurrence following radical prostatectomy.
Conclusion
CTAs may serve as biomarkers to differentiate between patients with recurrent and non-recurrent prostate cancer after surgery.
Supporting Evidence
- CEP55, NUF2, and PAGE4 were significantly associated with the risk of prostate cancer recurrence.
- The study identified CTAs as potential biomarkers for prostate cancer prognosis.
- Higher expression of CEP55 and NUF2 correlated with shorter biochemical recurrence-free time.
Takeaway
This study looks at special proteins that can help doctors tell if prostate cancer will come back after treatment.
Methodology
The expression of 5 CTAs was measured using quantitative multiplex real-time PCR on prostate tissue samples from 72 patients.
Potential Biases
Selection bias due to non-consecutive and non-prospective collection of patient samples.
Limitations
The study had a limited number of patients and selection bias due to the use of frozen tissue samples from high-risk cases.
Participant Demographics
72 patients with clinically localized prostate cancer, including 29 without recurrence and 43 with recurrence.
Statistical Information
P-Value
0.004 for CEP55, 0.024 for NUF2, 0.031 for PAGE4
Confidence Interval
CEP55 (1.50-8.60), NUF2 (1.11-4.67), PAGE4 (0.21-0.93)
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website